UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Circulation research, ISSN 0009-7330, 09/2016, Volume 119, Issue 6, pp. 751 - 763
Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Cell Line | Lipoproteins, HDL - administration & dosage | Antioxidants - metabolism | Humans | Mice, Inbred C57BL | Oxidative Stress - physiology | Lipoproteins, HDL - metabolism | Cholesterol - metabolism | Anti-Inflammatory Agents - metabolism | Mice, Knockout | Animals | Antioxidants - administration & dosage | Anti-Inflammatory Agents - administration & dosage | Mice | Infusions, Intravenous | Oxidative Stress - drug effects | Index Medicus | antioxidant | 10040 | inflammation | 10030 | 10184 | Integrative Physiology | cholesterol | 10034 | 10188 | apolipoprotein A-I | high-density lipoproteins
Journal Article
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 03/2009, Volume 29, Issue 3, pp. 416 - 423
Cardiometabolic risk | Intraabdominal obesity | Liver fat | Rimonabant | Dyslipidemia | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous | Blood. Blood coagulation. Reticuloendothelial system | Atherosclerosis (general aspects, experimental research) | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Blood and lymphatic vessels | Pyrazoles - therapeutic use | Obesity - drug therapy | Humans | Middle Aged | Body Weight - drug effects | Anti-Obesity Agents - adverse effects | Male | Tomography, X-Ray Computed | Insulin - blood | Obesity - blood | Anti-Obesity Agents - therapeutic use | Dyslipidemias - blood | C-Reactive Protein - metabolism | Liver - drug effects | Time Factors | Liver - diagnostic imaging | Adult | Female | Blood Pressure - drug effects | Intra-Abdominal Fat - drug effects | Pyrazoles - adverse effects | Dyslipidemias - drug therapy | Adiposity - drug effects | Double-Blind Method | Liver - metabolism | Obesity - physiopathology | Treatment Outcome | Apolipoproteins - blood | Intra-Abdominal Fat - metabolism | Adiponectin - blood | Blood Glucose - drug effects | Intra-Abdominal Fat - diagnostic imaging | Piperidines - therapeutic use | Piperidines - adverse effects | Triglycerides - blood | Cholesterol, HDL - blood | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Lipoproteins, LDL - blood | Dyslipidemias - physiopathology | Index Medicus
Journal Article
Nature reviews. Drug discovery, ISSN 1474-1776, 2014, Volume 13, Issue 6, pp. 445 - 464
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Recombinant Proteins - therapeutic use | Drugs, Investigational - adverse effects | Lipoproteins, HDL - agonists | Hypolipidemic Agents - metabolism | Lipoproteins, HDL - blood | Cardiovascular Diseases - prevention & control | Humans | Lipoproteins, HDL - metabolism | Drugs, Investigational - therapeutic use | Drugs, Investigational - metabolism | Recombinant Proteins - adverse effects | Phosphatidylcholine-Sterol O-Acyltransferase - genetics | Apolipoprotein A-I - genetics | Niacin - therapeutic use | Cardiovascular Diseases - blood | Lipoproteins, HDL - therapeutic use | Niacin - adverse effects | Recombinant Proteins - metabolism | Hypolipidemic Agents - adverse effects | Molecular Targeted Therapy - adverse effects | Cardiovascular Diseases - metabolism | Clinical Trials as Topic | Apolipoprotein A-I - metabolism | Apolipoprotein A-I - agonists | Niacin - metabolism | Up-Regulation - drug effects | Phosphatidylcholine-Sterol O-Acyltransferase - adverse effects | Animals | Models, Biological | Phosphatidylcholine-Sterol O-Acyltransferase - therapeutic use | Hypolipidemic Agents - therapeutic use | Cholesterol Ester Transfer Proteins - metabolism | Phosphatidylcholine-Sterol O-Acyltransferase - metabolism | Care and treatment | High density lipoproteins | Patient outcomes | Development and progression | Research | Cardiovascular diseases | Risk factors | Index Medicus
Journal Article
Pharmacological research, ISSN 1043-6618, 05/2017, Volume 119, pp. 208 - 218
Curcumin | High-density lipoprotein | Dyslipidemia | Atherosclerosis | Cholesterol efflux | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Dyslipidemias - drug therapy | Atherosclerosis - drug therapy | Antioxidants - chemistry | Curcumin - therapeutic use | Curcumin - chemistry | Humans | Curcumin - pharmacology | Lipoproteins, HDL - metabolism | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Antioxidants - pharmacology | Atherosclerosis - metabolism | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Antioxidants - therapeutic use | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Dyslipidemias - metabolism | Lipoproteins, HDL - analysis | Curcuma - chemistry | Hypertension | Medical colleges | Lecithin | Physiological aspects | Triglycerides | Research institutes | Plant lipids | Lipase | Apolipoproteins | Dextran | Blood cholesterol | Low density lipoproteins | Lipids | Annexins | Protein kinases | Lipoprotein A | Protein binding | Organic compounds | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 24, pp. 2255 - 2267
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | Metabolic diseases | General aspects | Medical sciences | Disorders of blood lipids. Hyperlipoproteinemia | Simvastatin - therapeutic use | Humans | Middle Aged | Male | Niacin - therapeutic use | Treatment Failure | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Niacin - adverse effects | Cholesterol, LDL - blood | Female | Brain Ischemia - chemically induced | Muscular Diseases - chemically induced | Drug Therapy, Combination | Brain Ischemia - epidemiology | Hypolipidemic Agents - adverse effects | Atherosclerosis - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Atherosclerosis - blood | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cholesterol, HDL - blood | Aged | Hypolipidemic Agents - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Control | Dosage and administration | Product/Service Evaluations | Drug therapy | Niacin | Cholesterol | Statins | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Simvastatin | Cardiovascular disease | Triglycerides | Coronary artery disease | Ischemia | Diet | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Lipoproteins (high density) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
The journal of clinical endocrinology and metabolism, ISSN 0021-972X, 05/2015, Volume 100, Issue 5, pp. 2006 - 2014
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Calcium - metabolism | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Phospholipids - pharmacology | Lipoproteins, HDL - pharmacology | Dose-Response Relationship, Drug | Young Adult | Signal Transduction - drug effects | Blood Platelets - metabolism | Adult | Female | Aged | Platelet Activation - drug effects | Platelet Aggregation - drug effects | p38 Mitogen-Activated Protein Kinases - metabolism | Blood Platelets - drug effects | Index Medicus | Abridged Index Medicus | Life Sciences | Food and Nutrition | oxidized phospholipids | High density lipoproteins | diabetes | hydroxy - octadecadienoic acid | platelets
Journal Article